高血压中补体与T淋巴细胞的相互作用

doi:10.3969/j.issn.1674-490X.2022.06.002

摘要/Abstract

摘要： 越来越多的证据表明,高血压及高血压终末器官损害的产生,不仅可以由血流动力学损伤介导,还可以由炎症损伤介导。炎症在高血压的病理生理学过程中起着重要作用,它通过激活机体内免疫反应而介导各种并发症。补体作为潜在的高血压调节因子以及先天性免疫与适应性免疫的交汇点,通过先天性免疫和适应性免疫来影响高血压的发生发展。现综述高血压发生发展过程中补体与获得性免疫细胞中的T淋巴细胞的相互作用,以期更好地了解补体和高血压的关系,为疾病诊疗提供新的思路。

关键词: 高血压, 补体, T淋巴细胞, 适应性免疫

Abstract: More and more evidences indicate that hypertension and end-organ damage of hypertension can be mediated not only by hemodynamic injury, but also by inflammation. Inflammation plays an important role in the pathophysiology of hypertension and mediates various complications by activating the immune response in the body. Complement, as a potential regulator of hypertension and the intersection of innate immunity and adaptive immunity, affects the occurrence and development of hypertension through both innate immunity and adaptive immunity. In this paper, we will review the interaction between complement and T lymphocytes in acquired immune cells during the occurrence and development of hypertension, in order to better understand the relationship between complement and hypertension, and provide new ideas for disease diagnosis and treatment.

Key words: hypertension, complement, T lymphocytes, adaptive immunity

中图分类号:

李丹云,朱成振,杨斓,郭皓. 高血压中补体与T淋巴细胞的相互作用[J]. 医学研究与教育, 2022, 39(6): 9-14.

参考文献

[1] WENZEL U O, BODE M, KÖHL J, et al. A pathogenic role of complement in arterial hypertension and hypertensive end organ damage[J]. Am J Physiol Heart Circ Physiol, 2017, 312(3): H349-H354. DOI: 10.1152/ajpheart.00759.2016.
[2] WENZEL U O, CLAUDIA K, MARLIES B. The role of complement in arterial hypertension and hypertensive end organ damage[J]. Br J Pharmacol, 2021, 178(14): 2849-2862. DOI: 10.1111/bph.15171.
[3] WENZEL U O, EHMKE H, BODE M. Immune mechanisms in arterial hypertension. Recent advances[J]. Cell Tissue Res, 2021, 385(2): 393-404. DOI: 10.1007/s00441-020-03409-0.
[4] GUZIK T J, HOCH N E, BROWN K A, et al. Role of the T cell in the genesis of angiotensin Ⅱ induced hypertension and vascular dysfunction[J]. J Exp Med, 2007, 204(10): 2449-2460. DOI: 10.1084/jem.20070657.
[5] YOUN J C, YU H T, LIM B J, et al. Immunosenescent CD8⁺ T cells and C-X-C chemokine receptor type 3 chemokines are increased in human hypertension[J]. Hypertension, 2013, 62(1): 126-133. DOI: 10.1161/HYPERTENSIONAHA.113.00689.
[6] STRAINIC M G, LIU J B, HUANG D P, et al. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4⁺ T cells[J]. Immunity, 2008, 28(3): 425-435. DOI: 10.1016/j.immuni.2008.02.001.
[7] KOLEV M, LE FRIEC G, KEMPER C. The role of complement in CD4⁺ T cell homeostasis and effector functions[J]. Semin Immunol, 2013, 25(1): 12-19. DOI: 10.1016/j.smim.2013.04.012.
[8] TLILI B, KASAL D A, LI M W, et al. T regulatory lymphocytes prevent angiotensin Ⅱ-induced hypertension and vascular injury[J]. Hypertens Dallas Tex 1979, 2011, 57(3): 469-76. DOI: 10.1161/HYPERTENSIONAHA.110.162941.
[9] COOPER M A, FEHNIGER T A, CALIGIURI M A. The biology of human natural killer-cell subsets[J]. Trends Immunol, 2001, 22(11): 633-640. DOI: 10.1016/s1471-4906(01)02060-9.
[10] SHAO J, NANGAKU M, MIYATA T, et al. Imbalance of T-cell subsets in angiotensin Ⅱ-infused hypertensive rats with kidney injury[J]. Hypertension, 2003, 42(1): 31-38. DOI: 10.1161/01.HYP.0000075082.06183.4E.
[11] KAMAT N V, THABET S R, XIAO L, et al. Renal transporter activation during angiotensin-Ⅱ hypertension is blunted in interferon-γ^-/- and interleukin-17A^-/- mice[J]. Hypertension, 2015, 65(3): 569-576. DOI: 10.1161/HYPERTENSIONAHA.114.04975.
[12] ZHANG J D, PATEL M B, GRIFFITHS R, et al. Tumor necrosis factor-α produced in the kidney contributes to angiotensin Ⅱ-dependent hypertension[J]. Hypertension, 2014, 64(6): 1275-1281. DOI: 10.1161/HYPERTENSIONAHA.114.03863.
[13] GIUSEPPINA A, CLAUDIA K. A novel “complement-metabolism-inflammasome axis” as a key regulator of immune cell effector function[J]. Eur J Immunol, 2016, 46(7): 1563-1573. DOI: 10.1002/eji.201546131.
[14] TRIANTAFILOU M, HUGHES T R, MORGAN B P, et al. Complementing the inflammasome[J]. Immunology, 2016, 147(2): 152-164. DOI: 10.1111/imm.12556.
[15] HESS C, KEMPER C. Complement-mediated regulation of metabolism and basic cellular processes[J]. Immunity, 2016, 45(2): 240-254. DOI: 10.1016/j.immuni.2016.08.003.
[16] KOLEV M, DIMELOE S, LE FRIEC G, et al. Complement regulates nutrient influx and metabolic reprogramming during Th1 cell responses[J]. Immunity, 2015, 42(6): 1033-1047. DOI: 10.1016/j.immuni.2015.05.024.
[17] LI K, ANDERSON K J, PENG Q, et al. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation[J]. Blood, 2008, 112(13): 5084-5094. DOI: 10.1182/blood-2008-05-156646.
[18] CROKER D E, HALAI R, KAESLIN G, et al. C5a2 can modulate ERK1/2 signaling in macrophages via heteromer formation with C5a1 and β-arrestin recruitment[J]. Immunol Cell Biol, 2014, 92(7): 631-639. DOI: 10.1038/icb.2014.32.
[19] KASTL S P, SPEIDL W S, KAUN C, et al. The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation[J]. J Thromb Haemost, 2006, 4(8): 1790-1797. DOI: 10.1111/j.1538-7836.2006.02046.x.
[20] HASHIMOTO M, HIROTA K, YOSHITOMI H, et al. Complement drives Th17 cell differentiation and triggers autoimmune arthritis[J]. J Exp Med, 2010, 207(6): 1135-1143. DOI: 10.1084/jem.20092301.
[21] GRAILER J J, BOSMANN M, WARD P A. Regulatory effects of C5a on IL-17A, IL-17F, and IL-23[J]. Front Immunol, 2013, 3: 387. DOI: 10.3389/fimmu.2012.00387.
[22] HERNANDEZ A L, KITZ A, WU C, et al. Sodium chloride inhibits the suppressive function of FOXP3+ regulatory T cells[J]. J Clin Invest, 2015, 125(11): 4212-4222. DOI: 10.1172/JCI81151.
[23] KASAL D A, BARHOUMI T, LI M W, et al. T regulatory lymphocytes prevent aldosterone-induced vascular injury[J]. Hypertension, 2012, 59(2): 324-330. DOI: 10.1161/HYPERTENSIONAHA.111.181123.
[24] MIAN M O R, BARHOUMI T, BRIET M, et al. Deficiency of T-regulatory cells exaggerates angiotensin Ⅱ-induced microvascular injury by enhancing immune responses[J]. J Hypertens, 2016, 34(1): 97-108. DOI: 10.1097/HJH.0000000000000761.
[25] WENZEL U, TURNER J E, KREBS C, et al. Immune mechanisms in arterial hypertension[J]. J Am Soc Nephrol, 2016, 27(3): 677-686. DOI: 10.1681/asn.2015050562.
[26] KHAN M A, SHAMMA T. Complement factor and T-cell interactions during alloimmune inflammation in transplantation[J]. J Leukoc Biol, 2019, 105(4): 681-694. DOI: 10.1002/JLB.5RU0718-288R.
[27] VAN DER TOUW W, CRAVEDI P, KWAN W H, et al. Cutting edge: receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells[J]. J Immunol, 2013, 190(12): 5921-5925. DOI: 10.4049/jimmunol.1300847.
[28] CHEN X H, RUAN C C, GE Q, et al. Deficiency of complement C3a and C5a receptors prevents angiotensin Ⅱ-induced hypertension via regulatory T cells[J]. Circ Res, 2018, 122(7): 970-983. DOI: 10.1161/CIRCRESAHA.117.312153.
[29] WU J, THABET S R, KIRABO A, et al. Inflammation and mechanical stretch promote aortic stiffening in hypertension through activation of p38 mitogen-activated protein kinase[J]. Circ Res, 2014, 114(4): 616-625. DOI: 10.1161/CIRCRESAHA.114.302157.
[30] LIU Y M, RAFFERTY T M, RHEE S W, et al. CD8⁺ T cells stimulate Na-Cl co-transporter NCC in distal convoluted tubules leading to salt-sensitive hypertension[J]. Nat Commun, 2017, 8: 14037. DOI: 10.1038/ncomms14037.
[31] WENZEL U O, BODE M, KURTS C, et al. Salt, inflammation, IL-17 and hypertension[J]. Br J Pharmacol, 2019, 176(12): 1853-1863. DOI: 10.1111/bph.14359.
[32] KIRABO A, FONTANA V, DE FARIA A P C, et al. DC isoketal-modified proteins activate T cells and promote hypertension[J]. J Clin Invest, 2014, 124(10): 4642-4656. DOI: 10.1172/jci74084.
[33] WANG H X, LI W J, HOU C L, et al. CD1d-dependent natural killer T cells attenuate angiotensin Ⅱ-induced cardiac remodelling via IL-10 signalling in mice[J]. Cardiovasc Res, 2019, 115(1): 83-93. DOI: 10.1093/cvr/cvy164.